Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Crispr Therapeutics AG (CRSP) Price & Performance

Cronos Group IncTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Crispr Therapeutics AG — how do they compare? Cronos Group Inc trades at $3.09 (market cap $1.14B), while Crispr Therapeutics AG trades at $53.84 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 4.6× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.

CRONCRSP
Market Cap
$1.14B$5.23B
Sector
HealthHealth
52-Week High
$3.27$76.78
52-Week Low
$2.30$44.34
Enterprise Value
$341.13M$3.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.

Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Returns comparison

Trailing returns across standard periods

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP